Search

Key Clinical Message Optimized treatments for relapsed isolated CNS lymphoma (RI‐SCNSL) remains under investigation. Temozolomide combination‐based therapy, which is often used in glioblastoma may be used as potential treatment in RI‐SCNSL. Abstract One of the most common types of non‐Hodgkin lymphoma (NHL) is diffuse large B‐cell lymphoma (DLBCL). Despite advances in treatment, relapsed isolated CNS lymphoma (RI‐SCNSL) from DLBCL remains an issue. The optimal approach in RI‐SCNSL remains an area of active investigation as currently there is no high level of evidence for the treatments due to lack of randomized studies. In this case report, we present a DLBCL patient with CNS recurrence treated radiotherapy and intrathecal methotrexate (MTX) followed by intravenous high‐dose MTX, rituximab, and temozolomide. To the best of our knowledge, this is the first case report describing RI‐SCNSL treated with the regiments above which also include temozolomide which is used for glioblastoma.

Abstract Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.